Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.

Journal of Alzheimer's Disease : JAD
Masafumi Ihara, Satoshi Saito

Abstract

Although more than 100 years have passed since Alois Alzheimer reported a case of Alzheimer's disease (AD), a definitive answer to the causes of cognitive impairment in the disease remains elusive. Despite significant enthusiasm and investment from the pharmaceutical industry, clinical trials of many disease-modifying drugs for AD have been largely unsuccessful. Drug repositioning (DR) or repurposing approaches are relatively inexpensive and more reliable compared to de novo drug development in AD. About 30% of clinical trials for AD in progress around the world use the DR method and hold potential in halting the current deadlock in treatment options. By using drugs approved for other indications, these clinical trials target dysregulated pathways in AD with different or a combination of modes of action, including anti-amyloid, cardiovascular, anti-tau, anti-inflammatory, immunomodulatory, metabolic, neuroprotective, and neurotransmission-based approaches. For instance, anti-diabetic drugs, such as insulin, metformin, liraglutide, and dapagliflozin, and cardiovascular drugs, such as cilostazol, candesartan, telmisartan, prazosin, and dabigatran, could serendipitously provide previously unearthed benefits in AD. This is in line ...Continue Reading

References

May 10, 2006·Archives of Internal Medicine·David C RadleyRandall S Stafford
May 7, 2008·Neurology·Steven C VladDavid T Felson
Nov 7, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kim N GreenFrank M LaFerla
Jun 30, 2009·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Tyler A Kokjohn, Alex E Roher
Nov 4, 2009·Journal of Diabetes Science and Technology·Suzanne M de la Monte, Jack R Wands
Feb 20, 2010·Nature Reviews. Drug Discovery·Steven M PaulAaron L Schacht
Oct 29, 2010·Trends in Pharmacological Sciences·André FischerLi-Huei Tsai
May 20, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yi-Fei DongShokei Kim-Mitsuyama
Oct 15, 2011·Nature Biotechnology·Kate S Gaudry
Mar 2, 2012·Nature Reviews. Drug Discovery·Jack W ScannellBrian Warrington
Jul 5, 2012·Annals of the New York Academy of Sciences·Paola GambaGabriella Leonarduzzi
Aug 14, 2012·Journal of the Neurological Sciences·Raj N KalariaMasafumi Ihara
Aug 14, 2013·Nature Reviews. Neurology·Raj N Kalaria, Masafumi Ihara
May 21, 2014·Journal of Diabetes Investigation·Kapil GudalaAnil Bhansali
Oct 31, 2014·Annals of Clinical and Translational Neurology·Diana W ShinemanHoward M Fillit
Oct 31, 2014·Annals of Clinical and Translational Neurology·Takakuni MakiMasafumi Ihara
Nov 2, 2014·BMC Medicine·Frances BunnCarol Brayne
Nov 5, 2014·Frontiers in Aging Neuroscience·Satoshi Saito, Masafumi Ihara
Nov 18, 2014·Biotechnology and Applied Biochemistry·Sibhghatulla ShaikhRoshan Jahan
Sep 1, 2013·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Akihiko TaguchiMasahiro Okada
Apr 22, 2015·Annals of Neurology·Eran BlacherAyelet Levy
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Shinji MatsunagaNakao Iwata
Dec 8, 2015·Journal of Alzheimer's Disease : JAD·Carola StockburgerWalter E Müller
Feb 3, 2016·Therapeutic Advances in Drug Safety·Amanda Hanora Lavan, Paul Gallagher
Jun 22, 2016·Nature Communications·Y Iturria-MedinaUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Aug 17, 2010·Pharmaceuticals·Sebastian Walther, Michael Halpern
Oct 8, 2016·Journal of Alzheimer's Disease : JAD·Patrick L McGeerEdith G McGeer
Apr 5, 2017·Journal of Alzheimer's Disease : JAD·Chunmei JiangBin Zhao
Apr 21, 2017·American Journal of Alzheimer's Disease and Other Dementias·W J Fessel
Sep 9, 2017·Journal of the American Geriatrics Society·Hui-Ting ChengChung-Hsuen Wu
Jan 18, 2018·Journal of Psychopharmacology·Simon Jc DaviesTarek K Rajji
Feb 3, 2018·Journal of Neurology·Konstantinos Ioannis AvgerinosVasileios-Arsenios Lioutas

❮ Previous
Next ❯

Citations

Mar 19, 2020·International Journal of Molecular Sciences·Masashi TanakaMasafumi Ihara
Aug 19, 2020·Alzheimer's Research & Therapy·Justin BauzonJeffrey Cummings
Dec 22, 2020·Frontiers in Neuroscience·Antonio MunafòGiuseppina Cantarella
Feb 20, 2021·World Journal of Microbiology & Biotechnology·Vitória S FolettoRosmari Hörner
Jun 8, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Satoshi SaitoMasafumi Ihara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Related Papers

Brain and nerve = Shinkei kenkyū no shinpo
Masafumi Ihara, Satoshi Saito
Brain and nerve = Shinkei kenkyū no shinpo
Akira Tamaoka
Biochimica Et Biophysica Acta
Jill K MorrisJeffrey M Burns
Journal of Alzheimer's Disease : JAD
Patricia L FernándezK S Rao
© 2021 Meta ULC. All rights reserved